Expert Q&As
First interactions with EMA - Q&A 4
What is a Pediatric Investigation Plan (PIP) and when should we plan for it in Europe?
Access decades of experience
What’s Inside the Q&A:
Mandatory PIP Timeline Requirements
Critical timing differences between EU and US pediatric planning. Why late Phase 1 submission is essential in Europe.
Legal Obligations vs. US System
How Europe's PIP requirements differ from US PREA rules, including scope that catch US companies off-guard.
Market Exclusivity Incentives
The rewards system for completing PIP obligations and how it differs between orphan and non-orphan drug classifications.
Implementation Planning
Operational considerations for pediatric studies and alignment with adult development timelines.
Download our Expert Q&A
Discover our latest news
Expert Q&As
First interactions with EMA - Q&A 1
What are the different regulatory pathways available when expanding to Europe and which one is the best fit for me?
Expert Q&As
First interactions with EMA - Q&A 2
How does the EU drug development landscape differ from the US ?
Expert Q&As
First interactions with EMA - Q&A 7
What regulatory pathway missteps should we avoid, and how can we streamline our EU dossier preparation?
